|Videos|May 21, 2020

COVID 19: The Psychology of Social Distancing

Vickie Mays, PhD, uses her training in clinical psychology to provide insight on the long-term cognitive impact of the coronavirus pandemic and outbreak response.

Segment Description: Vickie Mays, PhD, uses her training in clinical psychology to provide insight on the long-term cognitive impact of the coronavirus pandemic and outbreak response.

Related Coverage:

Taking Care of Mental Health While Treating COVID-19

These are trying times for health care workers. That’s been well documented.

However, as stressful as the past few weeks have been, with surges in the numbers of critically ill patients in hospitals and clinics because of the coronavirus disease 2019 (COVID-19) pandemic—and the inexcusable shortages in supplies of personal protective equipment (PPE), ventilators, and intensive care unit capacity that have put these patients and their caregivers at risk—one overlooked aspect of the crisis has been the surrogate role played by clinicians.

Care of those severely ill with COVID-19 requires more than just a pleasant and professional bedside manner. Because the virus is highly contagious, those who have progressed to severe disease are, by necessity, isolated: family and loved ones can’t be at their bedside offering comfort or, in the direst circumstances, to say goodbye.

Read the full article.

Study: COVID-19 Health Care Workers Face Higher Risk of Insomnia

Health care workers helping to fight coronavirus disease 2019 (COVID-19) are well aware they face a heightened risk of infection with SARS-CoV-2, as well as high levels of added stress.

Now, a new study shows another way the COVID-19 workload is affecting health care workers: insomnia.

A team of Chinese investigators found more than one-third of frontline health care workers responding to the coronavirus outbreak reported symptoms of insomnia. The findings were published in Frontiers in Psychiatry.

Read the full article.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.